{"componentChunkName":"component---src-templates-keyman-1-js","path":"/keymans/266226","result":{"data":{"keymans1Json":{"id":"266226","corporation_id":4432837,"relocation_at":"2023-05-25 00:00:00","name":"斎藤久","honorific":"常務グローバル事業統括長、執行役員","corporate_number":"7300001006281","company_name":"久光製薬株式会社","prefecture_name":"佐賀県","city_name":"鳥栖市","street_number":"田代大官町４０８番地","corporation_en_name":"","corporation_furigana":"ヒサミツセイヤク","change_cause":"","listing_type":"東証プライム","capital_stock":8473000000,"amount_of_sales":96647000000,"number_of_employees":"1506","logo_path":"https://d1fb6fvpaeq04z.cloudfront.net/7300001006281.png","corporation_detail_detail":"{\"jsic_l\": \"製造業\", \"jsic_m\": \"化学工業\", \"jsic_s\": \"医薬品製造業\", \"業種\": \"医薬品\", \"決算日\": \"2月末日\", \"設立日\": \"1944年05月22日\", \"source_url\": \"https://info.gbiz.go.jp/hojin/ichiran?hojinBango=7300001006281\", \"平均年齢\": \"39.4歳\", \"年間給与\": \"719万円\", \"上場年月日\": \"1962年09月01日\", \"会計監査人\": \"有限責任あずさ監査法人\", \"平均勤続年数\": \"15.8年\", \"最新開示期間\": \"2019年02月期 第３四半期\", \"採用している会計基準\": \"日本基準\", \"連結財務諸表の作成有無\": \"連結財務諸表の作成あり（連結開示）\", \"特定事業規則の適用（単体）\": \"なし\", \"特定事業規則の適用（連結）\": \"別記事業規則の適用なし\"}","average_age":"39.4歳","annual_income":"719万円","clothing_month":"2","source_url":"https://www.hisamitsu.co.jp/company/pdf/news_release_230525.pdf","corporation_source_url":"https://info.gbiz.go.jp/hojin/ichiran?hojinBango=7300001006281","patented":971,"registered_design":276,"registered_trademark":2837,"shikiho_stock_code":"4530","shikiho_site_url":"https://www.hisamitsu.co.jp/","shikiho_feature":"久光製薬株式会社は医薬品の会社である。主な事業内容は医薬品、医薬部外品、医療機器等の製造販売および輸出入。創業は1944年（昭和19年）5月22日（三養基製薬株式会社）","shikiho_tel":"0942-83-2101","shikiho_main_office":"","financial_statements":"[{\"title\": \"2024年２月期　決算短信〔日本基準〕（連結）\"}, {\"title\": \"2024年２月期　第３四半期決算短信〔日本基準〕（連結）\"}, {\"title\": \"2024年２月期　第２四半期決算短信〔日本基準〕（連結）\"}, {\"title\": \"2024年２月期　第１四半期決算短信〔日本基準〕（連結）\"}, {\"title\": \"2023年２月期　決算短信〔日本基準〕（連結）\"}, {\"title\": \"2023年２月期　第３四半期決算短信〔日本基準〕（連結）\"}, {\"title\": \"2023年２月期　第２四半期決算短信〔日本基準〕（連結）\"}, {\"title\": \"2023年２月期　第１四半期決算短信〔日本基準〕（連結）\"}, {\"title\": \"2022年２月期　決算短信〔日本基準〕（連結）\"}, {\"title\": \"2022年２月期　第３四半期決算短信〔日本基準〕（連結）\"}, {\"title\": \"2022年２月期　第２四半期決算短信〔日本基準〕（連結）\"}, {\"title\": \"2022年２月期　第１四半期決算短信（日本基準）（連結）\"}, {\"title\": \"2021年２月期　決算短信〔日本基準〕（連結）\"}, {\"title\": \"2021年２月期　第３四半期決算短信〔日本基準〕（連結）\"}, {\"title\": \"2021年２月期　第２四半期決算短信〔日本基準〕（連結）\"}, {\"title\": \"2021年２月期　第１四半期決算短信〔日本基準〕（連結）\"}, {\"title\": \"2020年２月期　決算短信〔日本基準〕（連結）\"}, {\"title\": \"2020年２月期　第３四半期決算短信〔日本基準〕（連結）\"}, {\"title\": \"2020年２月期　第２四半期決算短信〔日本基準〕（連結）\"}, {\"title\": \"2020年２月期　第１四半期決算短信〔日本基準〕（連結）\"}, {\"title\": \"2019年２月期　決算短信〔日本基準〕（連結）\"}, {\"title\": \"平成31年２月期　第３四半期決算短信〔日本基準〕（連結）\"}]","executive_biographies":"[{\"content\": \"ノーベンファーマシューティカルス副会長兼ヒサミツアメリカ会長兼久光製薬技術諮詢北京董事長兼ヒサミツファルマインドネシア取締役、執行役員国際事業部長\", \"relocation_at\": \"2014-05-22 00:00:00.000000\"}, {\"content\": \"ヒサミツユーエスインコーポレイテッド社長、取締役兼執行役員国際事業部長\", \"relocation_at\": \"2022-05-26 00:00:00.000000\"}, {\"content\": \"常務グローバル事業統括長、執行役員\", \"relocation_at\": \"2023-05-25 00:00:00.000000\"}]","shikiho_performances":"[{\"year\": 2010, \"capital_stock\": 8473000000, \"amount_of_sales\": 129834000000, \"number_of_employees\": null}, {\"year\": 2011, \"capital_stock\": 8473000000, \"amount_of_sales\": 137184000000, \"number_of_employees\": null}, {\"year\": 2012, \"capital_stock\": 8473000000, \"amount_of_sales\": 137794000000, \"number_of_employees\": null}, {\"year\": 2013, \"capital_stock\": 8473000000, \"amount_of_sales\": 142772000000, \"number_of_employees\": null}, {\"year\": 2014, \"capital_stock\": 8473000000, \"amount_of_sales\": 150635000000, \"number_of_employees\": null}, {\"year\": 2015, \"capital_stock\": 8473000000, \"amount_of_sales\": 156743000000, \"number_of_employees\": null}, {\"year\": 2016, \"capital_stock\": 8473000000, \"amount_of_sales\": 161852000000, \"number_of_employees\": null}, {\"year\": 2017, \"capital_stock\": 8473000000, \"amount_of_sales\": 112505000000, \"number_of_employees\": 1595}, {\"year\": 2018, \"capital_stock\": 8473000000, \"amount_of_sales\": 109269000000, \"number_of_employees\": 1596}, {\"year\": 2019, \"capital_stock\": 8473000000, \"amount_of_sales\": 109761000000, \"number_of_employees\": 1569}, {\"year\": 2020, \"capital_stock\": 8473000000, \"amount_of_sales\": 86694000000, \"number_of_employees\": 1583}, {\"year\": 2021, \"capital_stock\": 8473000000, \"amount_of_sales\": 90585000000, \"number_of_employees\": 1587}, {\"year\": 2022, \"capital_stock\": 8473000000, \"amount_of_sales\": 92979000000, \"number_of_employees\": 1521}, {\"year\": 2023, \"capital_stock\": 8473000000, \"amount_of_sales\": 96647000000, \"number_of_employees\": 1506}]","has_intent_tag":0,"has_public_department_phone_number":0}},"pageContext":{"slug":"266226"}},"staticQueryHashes":["512065377"]}